• Founded: 2016
  • Location: San Diego, CA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: DMD
  • Drug types: GEN, MUS
  • Lead product: Undisclosed
  • Product link: https://locanabio.com/pipeline/
  • Funding: $100M B Dec 2020; $55M A May 2019



job board

Short description:

RNA-targeting gene therapy

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Locanabio is developing gene therapies that correct RNA molecules. DNA mutations in gene coding sequences that cause disease are also present in the messenger RNA (mRNA) intermediate. While many current gene therapies target DNA, Locanabio is targeting RNA mutations. Locana’s CORRECTX platform enables screening of RNA binding proteins that precisely target and correct dysfunctional mRNA that causes many genetic diseases. Targeted RNA can be corrected through cleavage, splicing gene replacement, translation enhancement and editing, all of which Locanabio is investigating. Locanabio’s pipeline is in preclinical stages and focuses on therapies for neurodegenerative, neuromuscular and retinal diseases.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com